Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 28

1.

In-utero triple antiretroviral exposure associated with decreased growth among HIV-exposed uninfected infants in Botswana.

Powis KM, Smeaton L, Hughes MD, Tumbare EA, Souda S, Jao J, Wirth KE, Makhema J, Lockman S, Fawzi W, Essex M, Shapiro RL.

AIDS. 2016 Jan;30(2):211-20. doi: 10.1097/QAD.0000000000000895.

2.

Randomized noninferiority trial of two maternal single-dose nevirapine-sparing regimens to prevent perinatal HIV in Thailand.

Lallemant M, Le Coeur S, Sirirungsi W, Cressey TR, Ngo-Giang-Huong N, Traisathit P, Klinbuayaem V, Sabsanong P, Kanjanavikai P, Jourdain G, Mcintosh K, Koetsawang S; PHPT-5 study investigators..

AIDS. 2015 Nov 28;29(18):2497-507. doi: 10.1097/QAD.0000000000000865.

3.

Prevention of mother-to-child transmission of HIV type 1: the role of neonatal and infant prophylaxis.

Hurst SA, Appelgren KE, Kourtis AP.

Expert Rev Anti Infect Ther. 2015 Feb;13(2):169-81. doi: 10.1586/14787210.2015.999667. Review.

4.

Phylogenetic relatedness of circulating HIV-1C variants in Mochudi, Botswana.

Novitsky V, Bussmann H, Logan A, Moyo S, van Widenfelt E, Okui L, Mmalane M, Baca J, Buck L, Phillips E, Tim D, McLane MF, Lei Q, Wang R, Makhema J, Lockman S, DeGruttola V, Essex M.

PLoS One. 2013 Dec 11;8(12):e80589. doi: 10.1371/journal.pone.0080589.

5.

Short communication: effect of short-course antenatal zidovudine and single-dose nevirapine on the BED capture enzyme immunoassay levels in HIV type 1 subtype C infection.

Wang R, Weng J, Moyo S, Pain D, Barr CD, Maruapula D, Mongwato D, Makhema J, Novitsky V, Essex M.

AIDS Res Hum Retroviruses. 2013 Jun;29(6):901-6. doi: 10.1089/AID.2012.0294.

6.

Estimates of peripartum and postnatal mother-to-child transmission probabilities of HIV for use in Spectrum and other population-based models.

Rollins N, Mahy M, Becquet R, Kuhn L, Creek T, Mofenson L.

Sex Transm Infect. 2012 Dec;88 Suppl 2:i44-51. doi: 10.1136/sextrans-2012-050709.

7.

Adherence to antiretroviral therapy during and after pregnancy in low-income, middle-income, and high-income countries: a systematic review and meta-analysis.

Nachega JB, Uthman OA, Anderson J, Peltzer K, Wampold S, Cotton MF, Mills EJ, Ho YS, Stringer JS, McIntyre JA, Mofenson LM.

AIDS. 2012 Oct 23;26(16):2039-52. doi: 10.1097/QAD.0b013e328359590f. Review.

8.

Effects of short-course zidovudine on the selection of nevirapine-resistant HIV-1 in women taking single-dose nevirapine.

Micek MA, Blanco AJ, Carlsson J, Beck IA, Dross S, Matunha L, Seidel K, Montoya P, Gantt S, Matediana E, Jamisse L, Gloyd S, Frenkel LM.

J Infect Dis. 2012 Jun 15;205(12):1811-5. doi: 10.1093/infdis/jis282.

9.

Infant feeding practices were not associated with breast milk HIV-1 RNA levels in a randomized clinical trial in Botswana.

Rossenkhan R, Novitsky V, Sebunya TK, Leidner J, Hagan JE, Moyo S, Smeaton L, Lockman S, Musonda R, Ndung'u T, Gaseitsiwe S, Thior I, Mmalane M, Makhema J, Essex M, Shapiro R.

AIDS Behav. 2012 Jul;16(5):1260-4. doi: 10.1007/s10461-011-0035-7.

10.

HIV: prevention of mother-to-child transmission.

Teasdale CA, Marais BJ, Abrams EJ.

BMJ Clin Evid. 2011 Jan 17;2011. pii: 0909. Review.

11.

Replicative fitness costs of nonnucleoside reverse transcriptase inhibitor drug resistance mutations on HIV subtype C.

Armstrong KL, Lee TH, Essex M.

Antimicrob Agents Chemother. 2011 May;55(5):2146-53. doi: 10.1128/AAC.01505-10.

12.

Prevalence and clinical associations of CXCR4-using HIV-1 among treatment-naive subtype C-infected women in Botswana.

Lin NH, Smeaton LM, Giguel F, Novitsky V, Moyo S, Mitchell RM, Makhema J, Essex M, Lockman S, Kuritzkes DR.

J Acquir Immune Defic Syndr. 2011 May 1;57(1):46-50. doi: 10.1097/QAI.0b013e318214fe27.

13.

Increased risk of severe infant anemia after exposure to maternal HAART, Botswana.

Dryden-Peterson S, Shapiro RL, Hughes MD, Powis K, Ogwu A, Moffat C, Moyo S, Makhema J, Essex M, Lockman S.

J Acquir Immune Defic Syndr. 2011 Apr 15;56(5):428-36. doi: 10.1097/QAI.0b013e31820bd2b6.

14.

Effects of in utero antiretroviral exposure on longitudinal growth of HIV-exposed uninfected infants in Botswana.

Powis KM, Smeaton L, Ogwu A, Lockman S, Dryden-Peterson S, van Widenfelt E, Leidner J, Makhema J, Essex M, Shapiro RL.

J Acquir Immune Defic Syndr. 2011 Feb 1;56(2):131-8. doi: 10.1097/QAI.0b013e3181ffa4f5.

15.

Effectiveness of multidrug antiretroviral regimens to prevent mother-to-child transmission of HIV-1 in routine public health services in Cameroon.

Tchendjou P, Same-Ekobo C, Nga A, Tejiokem M, Kfutwah A, Nlend AN, Tsague L, Bissek AC, Ekoa D, Orne-Gliemann J, Rousset D, Pouillot R, Dabis F.

PLoS One. 2010 Apr 29;5(4):e10411. doi: 10.1371/journal.pone.0010411.

16.

Minor resistant variants in nevirapine-exposed infants may predict virologic failure on nevirapine-containing ART.

MacLeod IJ, Rowley CF, Thior I, Wester C, Makhema J, Essex M, Lockman S.

J Clin Virol. 2010 Jul;48(3):162-7. doi: 10.1016/j.jcv.2010.03.017.

17.

HIV-1 subtype C-infected individuals maintaining high viral load as potential targets for the "test-and-treat" approach to reduce HIV transmission.

Novitsky V, Wang R, Bussmann H, Lockman S, Baum M, Shapiro R, Thior I, Wester C, Wester CW, Ogwu A, Asmelash A, Musonda R, Campa A, Moyo S, van Widenfelt E, Mine M, Moffat C, Mmalane M, Makhema J, Marlink R, Gilbert P, Seage GR 3rd, DeGruttola V, Essex M.

PLoS One. 2010 Apr 12;5(4):e10148. doi: 10.1371/journal.pone.0010148.

18.

Nevirapine resistance by timing of HIV type 1 infection in infants treated with single-dose nevirapine.

Micek MA, Blanco AJ, Beck IA, Dross S, Matunha L, Montoya P, Seidel K, Gantt S, Matediane E, Jamisse L, Gloyd S, Frenkel LM.

Clin Infect Dis. 2010 May 15;50(10):1405-14. doi: 10.1086/652151.

19.

Ultrasensitive detection of minor drug-resistant variants for HIV after nevirapine exposure using allele-specific PCR: clinical significance.

Rowley CF, Boutwell CL, Lee EJ, MacLeod IJ, Ribaudo HJ, Essex M, Lockman S.

AIDS Res Hum Retroviruses. 2010 Mar;26(3):293-300. doi: 10.1089/aid.2009.0082.

20.

Efficacy and safety of 1-month postpartum zidovudine-didanosine to prevent HIV-resistance mutations after intrapartum single-dose nevirapine.

Lallemant M, Ngo-Giang-Huong N, Jourdain G, Traisaithit P, Cressey TR, Collins IJ, Jarupanich T, Sukhumanant T, Achalapong J, Sabsanong P, Chotivanich N, Winiyakul N, Ariyadej S, Kanjanasing A, Ratanakosol J, Hemvuttiphan J, Kengsakul K, Wannapira W, Sittipiyasakul V, Pornkitprasarn W, Liampongsabuddhi P, McIntosh K, Van Dyke RB, Frenkel LM, Koetsawang S, Le Coeur S, Kanchana S; PHPT-4 Study Team..

Clin Infect Dis. 2010 Mar 15;50(6):898-908. doi: 10.1086/650745.

Supplemental Content

Support Center